The future of cardiovascular medicine from the regulatory perspective

J Am Coll Cardiol

10 August 2016 - For many years, the American public and the entire world have benefited from the U.S. FDAs’ regulatory system for medical products.

The field of cardiovascular medicine has been an exemplary partner with the FDA for much of this time—a period marked by advances ranging from better diet to life-saving drugs, devices, and biologics, ultimately resulting in a nearly 40% reduction in the risk of death from cardiovascular disease in the first decade of the 21st century.

Largely due to the confluence of the FDA’s standards for evidence and wise leadership within the field, cardiovascular medicine has one of the strongest evidence bases among specialties.

Patients, physicians, and the public can have confidence in medical products used to prevent and treat cardiovascular disease because FDA standards for safety and effectiveness have been met, and also because the highly evolved approach to applying professional clinical practice guidelines in cardiovascular medicine provides important and useful clinical context for the use of medical products and behavioral interventions.

Read Journal the American Journal of Cardiology article

Michael Wonder

Posted by:

Michael Wonder